From:  Biosimilars in chronic spontaneous urticaria: current evidence, clinical implications and future perspectives

 Regulatory and policy landscape of biosimilars in the European Union (EU), Italy, and the United States (US).

AspectEUItalyUS
Marketing authorisationEMA centralised (mandatory)EMA approval valid nationallyFDA approval
BiosimilarityBased on totality of the evidenceSame as EMASame as FDA
InterchangeabilityScientific principle recognized; implementation determined nationallyPhysician-directed switching; no automatic substitutionSeparate FDA interchangeability designation
SwitchingPhysician decisionPhysician decisionPhysician decision
Pharmacy-level substitutionNot harmonized across EUNot permittedPermitted only for FDA-designated interchangeable biosimilars, according to state law
Pricing/AccessNot centralisedRegional/National controlMarket-based
ReimbursementNational health systemsNo active AIFA monitoring registry currently required for CSUIndividual payer systems

Data are from EMA biosimilar guidance, AIFA position papers and FDA biosimilar guidance [22, 25, 28].